Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADVMNASDAQ:IPHANASDAQ:JSPRNASDAQ:OMGA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$4.26+11.2%$4.48$3.52▼$14.16$88.62M1.14256,336 shs153,732 shsIPHAInnate Pharma$1.79-6.3%$1.98$1.29▼$3.51$150.06M0.23182,228 shs116,102 shsJSPRJasper Therapeutics$4.23+2.2%$5.60$4.05▼$30.70$63.54M2.23277,152 shs213,195 shsOMGAOmega Therapeutics$0.13-21.8%$0.20$0.10▼$3.23$6.92M1.652.67 million shs4.81 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies+11.23%-15.48%+2.40%-11.25%-68.21%IPHAInnate Pharma-6.28%-1.10%-14.35%-4.28%-33.21%JSPRJasper Therapeutics+2.17%-9.62%-24.19%-79.94%-83.85%OMGAOmega Therapeutics0.00%0.00%0.00%-84.02%-95.85%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADVMAdverum Biotechnologies4.3733 of 5 stars3.42.00.04.83.92.50.6IPHAInnate Pharma2.8317 of 5 stars3.85.00.00.01.81.70.0JSPRJasper Therapeutics2.8637 of 5 stars3.54.00.00.02.41.70.6OMGAOmega Therapeutics1.9711 of 5 stars3.40.00.00.00.61.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies 2.83Moderate Buy$27.83553.36% UpsideIPHAInnate Pharma 3.50Strong Buy$11.50542.46% UpsideJSPRJasper Therapeutics 3.00Buy$62.501,377.54% UpsideOMGAOmega Therapeutics 2.80Moderate Buy$9.207,260.00% UpsideCurrent Analyst Ratings BreakdownLatest JSPR, OMGA, ADVM, and IPHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025IPHAInnate PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.50 ➝ $11.503/11/2025JSPRJasper TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.002/13/2025JSPRJasper TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$38.002/6/2025IPHAInnate PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.50 ➝ $11.501/17/2025IPHAInnate PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.50 ➝ $11.501/10/2025JSPRJasper TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $40.001/9/2025JSPRJasper TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$68.00 ➝ $48.001/6/2025JSPRJasper TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$70.00 ➝ $70.00(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum Biotechnologies$1M88.62N/AN/A$8.26 per share0.52IPHAInnate Pharma$24.85M6.04N/AN/A$0.69 per share2.59JSPRJasper TherapeuticsN/AN/AN/AN/A$7.03 per shareN/AOMGAOmega Therapeutics$8.10M0.85N/AN/A$1.05 per share0.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$117.17M-$5.99N/AN/AN/AN/A-65.14%-40.52%5/8/2025 (Estimated)IPHAInnate Pharma-$8.19MN/A0.00∞N/AN/AN/AN/AN/AJSPRJasper Therapeutics-$64.46M-$4.86N/AN/AN/AN/A-67.64%-58.53%5/13/2025 (Estimated)OMGAOmega Therapeutics-$97.43M-$1.33N/AN/AN/A-902.93%-213.13%-41.24%6/20/2025 (Estimated)Latest JSPR, OMGA, ADVM, and IPHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/27/2025Q4 2024JSPRJasper Therapeutics-$1.27-$1.62-$0.35-$1.62N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/AJSPRJasper TherapeuticsN/AN/AN/AN/AN/AOMGAOmega TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A5.825.82IPHAInnate Pharma0.922.92N/AJSPRJasper TherapeuticsN/A7.617.61OMGAOmega Therapeutics1.001.611.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%IPHAInnate Pharma0.16%JSPRJasper Therapeutics79.85%OMGAOmega Therapeutics97.47%Insider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies4.20%IPHAInnate Pharma31.89%JSPRJasper Therapeutics2.70%OMGAOmega Therapeutics8.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies19020.80 million19.93 millionOptionableIPHAInnate Pharma22083.83 million57.10 millionNot OptionableJSPRJasper Therapeutics2015.02 million14.60 millionOptionableOMGAOmega Therapeutics12055.37 million50.66 millionOptionableJSPR, OMGA, ADVM, and IPHA HeadlinesRecent News About These CompaniesOmega Therapeutics Inc (OMGAQ)March 5, 2025 | investing.comHuge distressed drugmaker seeks sale in Chapter 11 bankruptcyFebruary 27, 2025 | msn.comIntrommune Therapeutics Announces Publication of OMEGA Study in Peanut Allergic Adults in Annals of Allergy, Asthma & ImmunologyFebruary 19, 2025 | markets.businessinsider.comOmega Therapeutics secures $9.8M in DIP financingFebruary 14, 2025 | msn.comOmega Therapeutics Hits Chapter 11February 10, 2025 | usaherald.comFlagship’s Omega Thera to file for bankruptcyFebruary 5, 2025 | thepharmaletter.comFlagship-backed Omega signals it’s headed toward bankruptcyFebruary 5, 2025 | biopharmadive.comThe OMGA Conundrum: Why Omega Therapeutics Inc’s Stock Is Making Headlines AgainFebruary 5, 2025 | bovnews.comNovo Partner Omega Waves Bankruptcy Flag from Sinking ShipFebruary 4, 2025 | biospace.comFlagship spinout Omega is days away from bankruptcy, it says in filingFebruary 4, 2025 | endpts.comWhat’s Behind the 11.36% Gain in Omega Therapeutics Inc (OMGA) Stock? Find Out Now!January 30, 2025 | bovnews.comOmega Therapeutics announces board reshuffle and new directorJanuary 29, 2025 | msn.comFlagship Pioneering partners with Cambridge, UK institutionsJanuary 25, 2025 | thepharmaletter.comOmega Therapeutics stock hits 52-week low at $0.52January 21, 2025 | msn.comOmega Therapeutics Appoints New Director Ravi MehrotraDecember 6, 2024 | tipranks.comOmega Pacific Reports Its Final Drill Hole Yielding Multiple Zones of Mineralization at Its Williams PropertyDecember 4, 2024 | accesswire.comOmega Pacific Announces 2024 Work Program Results From Its Lekcin PropertyNovember 19, 2024 | accesswire.comOmega Therapeutics Reports Third Quarter 2024 ResultsNovember 19, 2024 | markets.businessinsider.comOmega Therapeutics price target lowered to $4 from $9 at Piper SandlerNovember 16, 2024 | markets.businessinsider.comPiper Sandler Remains a Buy on Omega Therapeutics (OMGA)November 16, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJSPR, OMGA, ADVM, and IPHA Company DescriptionsAdverum Biotechnologies NASDAQ:ADVM$4.26 +0.43 (+11.23%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$4.22 -0.04 (-1.06%) As of 09:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Innate Pharma NASDAQ:IPHA$1.79 -0.12 (-6.28%) Closing price 04/2/2025 03:59 PM EasternExtended Trading$1.97 +0.18 (+10.06%) As of 09:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Jasper Therapeutics NASDAQ:JSPR$4.23 +0.09 (+2.17%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$4.17 -0.06 (-1.42%) As of 09:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.Omega Therapeutics NASDAQ:OMGA$0.12 -0.03 (-21.83%) Closing price 02/24/2025Extended Trading$0.12 0.00 (0.00%) As of 02/24/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Reasons Why Halliburton is a Good Buy in 2025 First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock Tesla Stock: What To Expect With Their Delivery Numbers Report Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future Analyst Targets Signal More Growth in CrowdStrike Stock NextEra Energy Stock Sees Spike in Bullish Call Activity 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
